Investigation of the functions of glycoproteins at tumor cell surfaces will concentrate on epiglycanin, a glycoprotein implicated in masking histocompatability antigens in allotransplantable TA3 mouse mammary carcinoma ascites cells. The possible role of epiglycanin and epiglycanin-like glycoproteins in allotransplatability in the mouse and metastasis in experimental animals and humans will be pursued by means of a radioimmune assay involving the use of an antibody to epiglycanin, specific for the carbohydrate moiety, and 125I-labelled epiglycanin. A possible relationship will be investigated, in several hundred patients with metastatic cancer, between the concentration of epiglycanin-like glycoproteins present in the ascites fluids and sera and the type and severity of the malignancy. The antibody will be purified, Fab fragments isolated, and the location(s) of the combining site(s) on the epiglycanin molecule determined by electron microscopy of the Fab antibody-epiglycanin complex. n antibody to the protein moiety of epiglycanin will be made from th deglycosylated glycoprotein. This antibody will be used, in a radioimmune assay, to study early peptide precursors to epiglycanin. We will also study the role of lipid intermediates to epiglycanin synthesis and the relative rates of synthesis of O-linked and N-linked chains. Inhibitors to epiglycanin biosynthesis will be sought. The amonio acid sequence will be determined on deglycosylated epiglycanin. The types of N-linked chains, the sequences of carbohydrate residues in the N-linked chains, accomplished mainly by the use of specific glycosyl hydrolases, and the possible presence of fucose (H blood group activity) in these chains will be determined. Comparison will be made of the types and concentrations of neutral glycolipids in strain specific and strain nonspecific TA3 ascites tumor lines.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA008418-20
Application #
3163318
Study Section
Physiological Chemistry Study Section (PC)
Project Start
1978-12-01
Project End
1985-11-30
Budget Start
1984-12-01
Budget End
1985-11-30
Support Year
20
Fiscal Year
1985
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
Watkins, S C; Slayter, H S; Codington, J F (1991) Intracellular pathway of a mucin-type membrane glycoprotein in mouse mammary tumor cells. Carbohydr Res 213:185-200
Beppu, M; Codington, J F; Lasky, R D et al. (1987) Epiglycanin-immunoreactive glycoproteins in mouse fetal tissues and fetal cells in culture. J Natl Cancer Inst 78:1169-75
Codington, J F; Deak, M R; Frim, D M et al. (1986) Evidence for the presence of an N-acetyllactosamine-type chain in epiglycanin. Arch Biochem Biophys 251:47-54
Schmit, A; Condington, J F; Slayter, H S (1986) Epiglycanin as a membrane glycoprotein. Isolation of plasma membrane from the TA3-Ha tumor cell. Carbohydr Res 151:173-84
Wold, J K; Slayter, H S; Codington, J F et al. (1985) Location of an epitopic site on epiglycanin by molecular immunoelectron microscopy. Biochem J 227:231-7
Walker-Nasir, E; Codington, J F; Lampert, L A et al. (1985) Effects of retinoic acid on ascites cells of the TA3 mouse mammary carcinoma. Experientia 41:402-4